文献速递哮喘

重度哮喘抗IL-5生物制剂剂量滴定:OPTIMAL开放标签随机对照试验

Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study).
PubMed 文献 · Eur Respir J · 2024-08-22

OPTIMAL是一项为期52周的开放标签随机对照试验,纳入抗IL-5治疗已达临床控制的重度嗜酸性哮喘患者,比较维持原给药间隔与按滴定算法逐步延长间隔、失控时再缩短的策略。73例入组患者中37例进入滴定组,78%耐受降剂量;滴定组急性发作比例在数值上高于对照组(32%对17%,p=0.13),无滴定相关严重不良事件,肺功能与症状评分两组稳定且相当。

要点

  • 抗IL-5治疗已达临床控制者可尝试按算法延长给药间隔,78%患者耐受降滴定。
  • 滴定组急性发作在数值上更多(32%对17%),但差异无统计学意义(p=0.13)。
  • 滴定期间肺功能与症状评分保持稳定,未观察到滴定相关严重不良事件。

核心结论

  • 抗IL-5生物制剂在重度哮喘临床控制患者中可按OPTIMAL算法进行剂量滴定,该研究为概念验证,为未来个体化给药间隔提供潜在框架。

研究设计与样本

  • 开放标签随机对照试验,为期52周,纳入抗IL-5治疗下达到临床控制(无急性发作且无维持口服糖皮质激素)的重度哮喘患者。
  • 73例患者入组,其中37例随机进入OPTIMAL滴定组,其余进入维持原给药间隔的对照组。

主要发现

  • 78%的患者耐受抗IL-5治疗降滴定。
  • 与对照组相比,OPTIMAL滴定组在研究期间急性发作在数值上更多(32%对17%;p=0.13)。
  • 未发生与滴定相关的严重不良事件,两组肺功能与症状评分在整个研究期间保持稳定且相当。

关键数值与推荐

  • 滴定算法逐步延长给药间隔,并在出现疾病失控迹象时再次缩短间隔,以评估可实现的最长给药间隔。
  • 临床控制定义为无急性发作且无维持口服糖皮质激素治疗。

临床怎么用

  • 对已达临床控制的抗IL-5治疗患者,可在密切监测下参考滴定算法尝试延长给药间隔,并以失控迹象作为回调依据。

局限性

  • 为试点性概念验证研究,样本量有限(73例入组、37例滴定组)。
  • 采用开放标签设计,急性发作差异未达统计学意义(p=0.13)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-interleukin (IL)-5 biologics effectively reduce exacerbations and the need for maintenance oral corticosteroids (mOCS) in severe eosinophilic asthma. However, it is unknown how long anti-IL-5 treatment should be continued. Data from clinical trials indicate a gradual but variable loss of control after treatment cessation. In this pilot study of titration, we evaluated a dose-titration algorithm in patients who had achieved clinical control on an anti-IL-5 biologic. METHODS: In this open-label randomised controlled trial conducted over 52 weeks, patients with clinical control (no exacerbations or mOCS) on anti-IL-5 treatment were randomised to continue with unchanged intervals or have dosing intervals adjusted according to a titration algorithm that gradually extended dosing intervals and reduced them again at signs of loss of disease control. The OPTIMAL algorithm was designed to down-titrate dosing until signs of loss of control, to enable assessment of the longest dosing interval possible. RESULTS: Among 73 patients enrolled, 37 patients were randomised to the OPTIMAL titration arm; 78% of patients tolerated down-titration of treatment. Compared to the control arm, the OPTIMAL arm tended to have more exacerbations during the study (32% versus 17%; p=0.13). There were no severe adverse events related to titration, and lung function and symptoms scores remained stable and comparable in both study arms throughout. CONCLUSION: This study serves as a proof of concept for titration of anti-IL-5 biologics in patients with severe asthma with clinical control on treatment, and the OPTIMAL algorithm provides a potential framework for individualising dosing intervals in the future.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Soendergaard MB, Bjerrum AS, Rasmussen LM, et al. Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study). Eur Respir J. 2024. PMID: 38843910. doi:10.1183/13993003.00404-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。